Key clinical point: Adding ribociclib to fulvestrant in the first or second line improves overall survival of advanced breast cancer in postmenopausal women.
Major finding: Median overall survival was not reached with ribociclib/fulvestrant versus 40 months for fulvestrant/placebo.
Study details: A randomized, phase 3 trial in 726 postmenopausal women with advanced de novo or relapsed breast cancer.
Disclosures: MONALEESA-3 is supported by Novartis. Dr. Slamon disclosed a consulting or advisory role, research funding, honoraria, and travel expenses from Novartis and others. Dr. Loibl disclosed honoraria and research grants from Novartis and others.
Slamon DJ et al. ESMO 2019, Abstract LBA7_PR.